DISCOVER A NEW WAY TO HELP
If you are a healthy male or female (of non-childbearing potential) aged between 18 and 65, then you may be eligible to participate in a clinical trial investigating a new drug being developed for the treatment of autoimmune and inflammatory diseases.
Study Payment £4065
Plus Travel Expenses.
CLINICAL TRIAL information
Simbec-Orion Clinical Pharmacology will soon be running a two part study to investigate a drug called MB272.
The overall objectives of the study are to determine the safety, tolerability and concentration in the blood of the study drug when evaluated in different conditions i.e., different dose strengths, following administration of single and multiple doses, and following administration in two different forms.
The study also aims to evaluate the effect of the study drug on the body, through the collection of blood samples at different times through the day.
The levels of the study drug in the blood will be measured at different times throughout the study in order to evaluate the study objectives.
The study drug is being developed for the treatment of a range of different diseases which can be broadly categorised as autoimmune and inflammatory diseases.
This study will be split into 2 separate parts, (Part A and Part B) and you will only be able to participate in one part of the study.
We Have successfully enrolled 93 Volunteers on to this study to date.
The purpose of Part A is to evaluate the study objectives when MB272 is given as a single dose on one occasion at different dose strengths and by different routes of administration.
Part A will consist of 7 planned groups of up to 8 participants per group: each investigating a different dose strength of MB272 starting at the lowest dose and gradually increasing in each group. 6 out of the 7 groups will receive MB272 or a placebo (which contains no active drug) intravenously on once (Day 1) with 1 group receiving MB272 or a placebo subcutaneously once (Day 1).
Administration in a subcutaneous form will occur whilst the intravenous infusion groups are ongoing.
If you participate in this part of the study, you will be required to stay at the Simbec-Orion clinical unit for a period of 6 days (5 overnight stays – Day -1 to Day 5) for the treatment period, followed by 6 return day visits and a final post-study follow-up visit.
You should therefore ensure that you are able to commit to completing all visits before agreeing to participate in this study.
CLINICAL TRIAL timeline
Cohort 9 Screening from: 19th September 2023
Into Simbec: 16th October
Leave Simbec: 21st October
Return Visits: October 24th and 31st, November 7th, 14th and 28th, December 12th
Post Study Visit: January 9th
Into Simbec: 23rd October
Leave Simbec: 28th October
Return Visits: October 31st, November 7th, 14th and 21st, December 5th and 19th
Post Study Visit: January 16th
Into Simbec: 25th October
Leave Simbec: 30th October
Return Visits: November 2nd, 9th, 16th and 23rd, December, 7th and 21st
Post Study Visit: January 18th
Cohort 10 currently planned for screening in January 2024, dates to be confirmed soon. Applications still being accepted
in the meantime.
If you fully complete this study, you will receive a maximum inconvenience payment of £4065.
We also pay additional travel expenses for every visit up to a maximum of £50.
Thank you for your time to register your interest in this trial please complete the below form.
OR to speak to a member of the Enrolment Team for more information or regarding any questions or queries please ring 0800 691995 and please select option 1. Alternatively drop us an email: firstname.lastname@example.org